|
Anaplastic astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Total MGMT protein was quantified by IHC on 982 glioblastomas (GBM) and 199 anaplastic astrocytomas.
|
30500933 |
2019 |
|
Anaplastic astrocytoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In a phase II study for patients with relapsed small cell lung cancer (SCLC), the administration of Temozolomide, an alkylating agent used in gliomas and anaplastic astrocytoma, showed a effective activity when O(6) -methylguanine-DNA methyltransferase (MGMT) gene promoter was methylated.
|
26152836 |
2015 |
|
Anaplastic astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.
|
24748470 |
2014 |
|
Anaplastic astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Our study confirms the utility of IDH1 mutations and MGMT methylation in predicting the prognosis of Group 1 patients (GBM + AA) and demonstrated that IDH1 mutations may serve as a more reliable prognostic factor for such patients.
|
24160898 |
2013 |
|
Anaplastic astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current standard of care for elderly patients with malignant astrocytoma involves a treatment strategy based on the MGMT gene promoter methylation status.
|
24152817 |
2013 |
|
Anaplastic astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, there is only anecdotal information about MGMT methylation status and TP53 mutations during progression of low-grade diffuse astrocytoma (AII) to anaplastic astrocytoma (AIII) and secondary glioblastoma (sGB).
|
20593220 |
2011 |
|
Anaplastic astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immediately after the operation, mRNA expression for drug-resistance genes was investigated in frozen samples of malignant gliomas from 55 patients (30 glioblastoma multiformes, 20 anaplastic astrocytomas and 5 anaplastic oligodendroglial tumors) by real-time quantitative RT-PCR with specific primers for MGMT.
|
18575733 |
2008 |
|
Anaplastic astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas.
|
17691113 |
2007 |
|
Anaplastic astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Promoter methylation of the deoxyribonucleic acid (DNA) repair gene, O(6)-methylguanine-DNA methyltransferase (MGMT), is associated with improved outcome of patients with glioblastoma multiforme and anaplastic astrocytoma treated with temozolomide (TMZ).
|
17721049 |
2007 |
|
Anaplastic astrocytoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Using the methylation-specific polymerase chain reaction, we assayed promoter hypermethylation of the MGMT gene in tumor deoxyribonucleic acid from 116 adult patients with supratentorial high-grade astrocytic tumors (42 anaplastic astrocytomas [AAs] and 74 glioblastomas multiforme [GBMs]).
|
14744281 |
2004 |
|
Anaplastic astrocytoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MGMT expressing cell population was markedly decreased in GBM compared with AA (26.1% vs 62.1%).
|
12579307 |
2003 |
|
Anaplastic astrocytoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression.
|
1501894 |
1992 |